Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 6:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 160 matching trials from the live ClinicalTrials.gov search.
Conditions
Schizophrenia
Interventions
Modafinil, Placebo
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Diego, California
Conditions
Narcolepsy
Interventions
JZP258
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
31
States / cities
Culver City, California • Encino, California • Huntington Beach, California + 27 more
Completed Phase 1Phase 2 Interventional Results available

Flumazenil for the Treatment of Primary Hypersomnia

NCT01183312
Conditions
Hypersomnia, Primary Hypersomnia, Idiopathic Hypersomnia, Narcolepsy Without Cataplexy
Interventions
Flumazenil
Drug
Lead sponsor
Lynn Marie Trotti
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Major Depressive Disorder, Excessive Sleepiness
Interventions
GATE-101
Drug
Lead sponsor
Syndeio Biosciences, Inc
Industry
Eligibility
18 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Eatontown, New Jersey
Completed Phase 4 Interventional Results available

Lemborexant Shift Work Treatment Study

NCT05344443
Conditions
Shift-Work Related Sleep Disturbance
Interventions
Lemborexant, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
20 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Conditions
Bipolar Disorder, Insomnia, Hypersomnia, Sleep Problems
Interventions
Body Scan (BS) Meditation Intervention, Brief Supportive Psychotherapy (SP)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Treating Sleep Apnea on Cognition in Patients With Dementia

NCT00477828
Conditions
Dementia, Sleep Apnea
Interventions
Continuous positive airway pressure
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
San Diego, California
Conditions
Narcolepsy Type 2
Interventions
ALKS 2680, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
33
States / cities
Little Rock, Arkansas • Los Angeles, California • Redwood City, California + 29 more
Conditions
End Stage Renal Disease
Interventions
using cool versus warm dialysate during hemodialysis
Procedure
Lead sponsor
Emory University
Other
Eligibility
21 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Myotonic Dystrophy, Type 1 (DM1), Myotonic Dystrophy
Interventions
ERX-963, Placebo
Drug
Lead sponsor
Expansion Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Palo Alto, California • Miami, Florida • Iowa City, Iowa + 1 more
Conditions
Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
Interventions
TAK-360, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 71 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
17
States / cities
Chula Vista, California • Colorado Springs, Colorado • Brandon, Florida + 13 more
Conditions
Narcolepsy
Interventions
MK-6552, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
5
States / cities
Colorado Springs, Colorado • Brandon, Florida • Atlanta, Georgia + 2 more
Conditions
Idiopathic Hypersomnia
Interventions
JZP-258, Placebo Oral Solution
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
40
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more
Conditions
Narcolepsy Type 2
Interventions
ALKS 2680 Dose 1, ALKS 2680 Dose 2, ALKS 2680 Dose 3, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
22
States / cities
Cullman, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

The Healthy Patterns Sleep Study

NCT03682185
Conditions
Dementia, Alzheimer Disease, Circadian Rhythm Disorders, Circadian Rhythm Sleep Disorder, Insomnia, Hypersomnia, Cognitive Impairment, Cognitive Decline, Mild Cognitive Impairment, Frontotemporal Dementia, Neurocognitive Disorders, Vascular Dementia, Sleep Disorder, Memory Impairment
Interventions
Attention-Control Condition, Timed Activity Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 110 Years
Enrollment
421 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Not applicable Interventional Accepts healthy volunteers

Nextsense Brain-sensing Buds Study

NCT06602960
Conditions
Sleep, Sleep Quality, Sleepiness, Daytime, Technology
Interventions
Accurate Sleep Data Feedback, Inflated Sleep Data Feedback, Deflated Sleep Data Feedback, Accurate Sleep Data Feedback + Sleep-related Educational Information
Behavioral
Lead sponsor
NextSense, Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Narcolepsy
Interventions
JNJ-17216498, Modafinil
Drug
Lead sponsor
Alza Corporation, DE, USA
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more
Conditions
Parkinson's Disease
Interventions
modafinil, methylphenidate
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Narcolepsy
Interventions
HBS-201
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
15
States / cities
San Ramon, California • Brandon, Florida • Miami, Florida + 12 more
Conditions
Excessive Daytime Sleepiness, Parkinson Disease
Interventions
BEN-2001, Placebo
Drug
Lead sponsor
BenevolentAI Bio
Industry
Eligibility
50 Years to 80 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Miami, Florida
Conditions
EDS, Cataplexy, Fatigue, Narcolepsy
Interventions
HBS-301, Placebo
Drug · Other
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
51
States / cities
Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 46 more
Conditions
Narcolepsy
Interventions
E2086, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
17
States / cities
Santa Ana, California • Brandon, Florida • Medley, Florida + 12 more
Conditions
Cerebral Stroke, Stroke, Acute, Cerebrovascular Stroke, Ischemic Attack, Transient
Interventions
NXY-059
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 95 more
Conditions
Excessive Daytime Sleepiness, Obstructive Sleep Apnea, Impaired Cognitive Function
Interventions
Solriamfetol, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Los Angeles, California • Santa Ana, California • Jacksonville, Florida + 11 more